Immatics (IMTX) Price & Analysis

Compare

294 Followers

IMTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.30 - $13.09

Previous CloseN/A

Volume408.80K

Average Volume (3M)477.12K

Market Cap

$717.15M

Enterprise Value$112.73M

Total Cash (Recent Filing)$543.76M

Total Debt (Recent Filing)$18.39M

Price to Earnings (P/E)53.8

Beta1.67

Next Earnings

Nov 18, 2025

EPS Estimate

-0.44

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.68

Shares Outstanding121,550,170

10 Day Avg. Volume669,050

30 Day Avg. Volume477,123

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.16

Enterprise Value/Revenue0.78

Enterprise Value/Gross Profit0.78

Enterprise Value/Ebitda-25.11

Forecast

1Y Price Target

$10.33

Price Target Upside75.08% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical DataUpdated Phase Ib data for IMA203 is viewed as encouraging and supports its development in melanoma.

Financial StabilityIMTX ended 1Q25 with $588.1M in cash and equivalents, providing a cash runway into the second half of 2027.

Market PositionIMTX is considered a leader in TCR therapeutics, with a broad platform encompassing both TCR T-cell therapy and TCR bispecifics.

Bears Say

Clinical Trial ProgressThe Phase III SUPRAME study evaluating IMA203 in cutaneous melanoma is on track to complete enrollment by the end of 2026, indicating a lengthy timeline for potential results.

Dose Escalation ChallengesThe dose escalation study for IMA402 continues to progress with the maximal tolerated dose not yet reached, suggesting ongoing challenges in finding optimal dosing.

Immatics News

Immatics reports Q2 EPS (EUR 0.58) vs (EUR 0.17) last year

Reports Q2 revenue EUR 4.737M vs EUR 18.755M last year. “The presentation of positive and extended follow-up Phase...

3d ago

IMTX

Immatics Reports Q2 2025 Financial Results and Business Update

Immatics ( ($IMTX) ) just unveiled an announcement. On August 13, 2025, Immatics N.V. released its financial results...

3d ago

IMTX

IMTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Immatics N.V. (IMTX) is scheduled to report 2nd quarter earnings on 08/12/2025. Regarding Q2 estimates, Wall Street analysts...

6d ago

IMTX

Immatics N.V. Shareholders Approve Key Resolutions at June 2025 AGM

The latest announcement is out from Immatics ( ($IMTX) ). On June 18, 2025, Immatics N.V. held its...

2M ago

IMTX

Immatics Announces Annual General Meeting for June 2025

The latest announcement is out from Immatics ( ($IMTX) ). On June 2, 2025, Immatics N.V. announced the...

2M ago

IMTX

Immatics Presents Promising IMA203 Data at ASCO 2025

The latest announcement is out from Immatics ( ($IMTX) ). On May 31, 2025, Immatics N.V. presented expanded...

3M ago

IMTX

Immatics announces presentation of data from ongoing Phase 1b trial on IMA203

Immatics (IMTX) announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME...

3M ago

IMTX

Immatics initiated with a Buy at Deutsche Bank

Deutsche Bank initiated coverage of Immatics (IMTX) with a Buy rating and $10 price target The firm likes...

3M ago

IMTX

Immatics: Promising Pipeline and Financial Stability Drive Buy Rating

Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Immatics (IMTX – Research Report) on May 13...

3M ago

IMTX

Immatics Reports Increased Q1 2025 Loss Amid Rising R&D Costs

Immatics ( ($IMTX) ) just unveiled an announcement. On May 13, 2025, Immatics N.V. released its interim financial...

3M ago

IMTX

Immatics reports Q1 EPS (EUR 0.33) vs (EUR 0.03) last year

Reports Q1 revenue EUR 18.582M vs EUR 30.269M last year. “Our focus in the first quarter of 2025...

3M ago

IMTX

Immatics: Strong Buy Rating Backed by Pipeline Progress and Financial Stability

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on IMTX stock, giving a Buy rating on...

5M ago

IMTX

Immatics Reports Strong 2024 Financial Results and Progress

Immatics N.V. ( ($IMTX) ) has released its Q4 earnings. Here is a breakdown of the information Immatics...

5M ago

IMTX

Immatics files $500M mixed securities shelf

08:05 EDT Immatics (IMTX) files $500M mixed securities shelf Published first on TheFly – the ultimate source for...

5M ago

IMTX

IMTX FAQ

What was Immatics N.V.’s price range in the past 12 months?

Immatics N.V. lowest stock price was $3.30 and its highest was $13.09 in the past 12 months.

What is Immatics N.V.’s market cap?

Immatics N.V.’s market cap is $717.15M.

When is Immatics N.V.’s upcoming earnings report date?

Immatics N.V.’s upcoming earnings report date is Nov 18, 2025 which is in 94 days.

How were Immatics N.V.’s earnings last quarter?

Immatics N.V. released its earnings results on Aug 13, 2025. The company reported -$0.676 earnings per share for the quarter, missing the consensus estimate of -$0.354 by -$0.322.

Is Immatics N.V. overvalued?

According to Wall Street analysts Immatics N.V.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immatics N.V. pay dividends?

Immatics N.V. does not currently pay dividends.

What is Immatics N.V.’s EPS estimate?

Immatics N.V.’s EPS estimate is -0.44.

How many shares outstanding does Immatics N.V. have?

Immatics N.V. has 121,550,170 shares outstanding.

What happened to Immatics N.V.’s price movement after its last earnings report?

Immatics N.V. reported an EPS of -$0.676 in its last earnings report, missing expectations of -$0.354. Following the earnings report the stock price went down -4.984%.

Which hedge fund is a major shareholder of Immatics N.V.?

Currently, no hedge funds are holding shares in IMTX

Immatics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-17.34%

Trailing 12-Months

Asset Growth

-0.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immatics N.V.

Immatics N.V. (IMTX) is a biotechnology company that operates in the field of cancer immunotherapy. The company specializes in the discovery and development of T-cell redirecting cancer immunotherapies. Immatics is focused on advancing a pipeline of Adoptive Cell Therapies (ACT) and TCR Bispecifics, which are designed to target solid tumors. Leveraging its proprietary XPRESIDENT and XCEPTOR platforms, Immatics identifies and validates novel cancer targets, aiming to provide new treatment options for cancer patients.

Immatics (IMTX) Earnings & Revenues

Historic Earnings Reports

IMTX Stock 12 Month Forecast

Average Price Target

$10.33

▲(75.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","16":"$16","6.25":"$6.25","9.5":"$9.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.25,9.5,12.75,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.48,7.135384615384615,7.790769230769231,8.446153846153846,9.101538461538462,9.756923076923076,10.412307692307692,11.067692307692308,11.723076923076924,12.378461538461538,13.033846153846154,13.689230769230768,14.344615384615384,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.48,6.776153846153846,7.072307692307692,7.368461538461538,7.664615384615384,7.96076923076923,8.256923076923076,8.553076923076922,8.849230769230768,9.145384615384614,9.44153846153846,9.737692307692308,10.033846153846154,{"y":10.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.48,6.443076923076924,6.406153846153846,6.36923076923077,6.332307692307692,6.295384615384616,6.258461538461539,6.2215384615384615,6.184615384615385,6.147692307692308,6.110769230769231,6.073846153846154,6.036923076923077,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.81,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.09,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.21,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.32,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.11,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.01,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >